SCHEMBL4521101

SCHEMBL4521101

NC(=O)[CH]CCCCC(N)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 3/20 0.50
SOAT1 P35610 2/20 0.50
KMT2A Q03164 2/20 0.50
CYP1A2 P05177 2/20 0.50
CYP2C19 P33261 2/20 0.50
MEN1 O00255 1/20 0.50
TP53 P04637 1/20 0.50
CYP3A4 P08684 1/20 0.50
KDM4E B2RXH2 2/20 0.45
CNR1 P21554 1/20 0.42
TARDBP Q13148 1/20 0.35
MAPT P10636 3/20 0.34
ABCC4 O15439 1/20 0.34
ALDH1A1 P00352 2/20 0.34
TBXAS1 P24557 1/20 0.33
ABHD16A O95870 1/20 0.33
POLB P06746 2/20 0.31
GMNN O75496 1/20 0.31
USP2 O75604 1/20 0.31
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7354572 0.92 CNR1 (0.43) FAAHSOAT1KMT2ACYP1A2CYP2C19
SCHEMBL1259870 0.83
SCHEMBL1629675 0.79
SCHEMBL1416084 0.77
SCHEMBL3501931 0.77 MAOA (0.45) KMT2ACYP1A2MEN1ALDH1A1LMNA
SCHEMBL125606 0.76 KMT2A (0.48) FAAHSOAT1KMT2ACYP1A2CYP2C19
SCHEMBL15262896 0.76 FAAH (0.78) FAAHSOAT1KMT2ACYP1A2CYP2C19
SCHEMBL15262992 0.76 FAAH (0.78) FAAHSOAT1KMT2ACYP1A2CYP2C19
SCHEMBL2088620 0.76 FAAH (0.78) FAAHSOAT1KMT2ACYP1A2CYP2C19
SCHEMBL1444474 0.76 FAAH (0.78) FAAHSOAT1KMT2ACYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090036353-A1 Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers NOVO NORDISK A/S (DK) 2009-02-05 US disclosed
EP-1853321-A2 INSULINOTROPIC AGENTS CONJUGATED WITH STRUCTURALLY WELL DEFINED BRANCHED POLYMERS NOVO NORDISK A/S (DK) 2007-11-14 EP disclosed
EP-1843790-A2 INSULIN DERIVATIVES CONJUGATED WITH STRUCTURALLY WELL DEFINED BRANCHED POLYMERS NOVO NORDISK A/S (DK) 2007-10-17 EP disclosed
WO-2006087354-A2 INSULINOTROPIC AGENTS CONJUGATED WITH STRUCTURALLY WELL DEFINED BRANCHED POLYMERS NOVO NORDISK A/S (DK) 2006-08-24 WO disclosed
WO-2006079641-A2 INSULIN DERIVATIVES CONJUGATED WITH STRUCTURALLY WELL DEFINED BRANCHED POLYMERS NOVO NORDISK A/S (DK) 2006-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090036353-A1 Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers INSR, IAPP, IGF1R FAAH 3449/4885SOAT1 988/4885KMT2A 4457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.